News Headlines Article

FDA panel lets Avandia stay on market
Modern Healthcare

In a split vote, the majority of a 33-member Food and Drug Administration advisory panel has recommended keeping the controversial diabetes drug Avandia on the market. The decision comes on heels of an earlier vote today in which the majority of panel members said Avandia, made by GlaxoSmithKline, is more likely than its competitors to cause heart attacks in patients using the drug.